A Phase 1 Study of MVB-101 Administered Intraprostatically in Patients With Localized Prostate Cancer Who Are Scheduled for Radical Prostatectomy
An Open-Label, Non-randomized, Multi-Center Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand Drug Conjugate MVB-101 Injected Into the Prostate of Patients With Localized Cancer of the Prostate Who Are Scheduled for Prostatectomy
This Phase 1, open-label, non-randomized, multicenter study will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of MVB-101 administered by direct intraprostatic injection in adults with previously untreated localized adenocarcinoma of the prostate who are scheduled to undergo radical prostatectomy. Participants will receive MVB-101 once weekly for 4 weeks. Part A will use an i3+3 dose-escalation design to evaluate dose levels of 1, 2, 4, and 8 mg and determine the maximum tolerated dose and recommended Phase 2 dose. Part B will use a Simon two-stage dose-expansion design at one or more selected dose levels to further characterize safety and preliminary efficacy. Participants will undergo safety, pharmacokinetic, multiparametric magnetic resonance imaging, pathological, prostate-specific antigen, and patient-reported outcome assessments.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen (PSMA) and folate receptor alpha (FR-alpha) and carrying monomethyl auristatin E (MMAE). MVB-101 will be administered by direct injection into the prostate under transrectal ultrasound guidance, at a fixed total injection volume of 10 mL (5 mL per lobe), once per week for 4 weeks.
Part A will enroll up to 30 participants. Planned dose levels are 1, 2, 4, and 8 mg per dose. The dose-limiting toxicity evaluation period is Day 1 through Day 29. Accelerated titration rules will be applied to the first two dose levels, and an i3+3 design will guide dose selection. Higher, lower, or intermediate dose levels may be added based on emerging data and Safety Monitoring Committee recommendations. The recommended Phase 2 dose may be the same as or lower than the maximum tolerated dose.
Part B will enroll up to 29 participants per dose group at one or more selected dose levels and will use a Simon two-stage design to better estimate the recommended Phase 2 dose and further characterize safety and preliminary efficacy.
The study includes screening, treatment, safety follow-up approximately 28 days after the last dose, post-treatment multiparametric MRI and PSA assessment, and planned radical prostatectomy at approximately Day 90 (12 weeks). If radical prostatectomy is not performed, a post-treatment prostate biopsy will be obtained as close as possible to the planned prostatectomy date. End of study occurs after completion of safety follow-up, post-treatment MRI and PSA assessment, and prostatectomy or post-treatment biopsy.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Aimee Murphy
- 전화번호: 925-818-4403
- 이메일: amurphy@mvbiotx.com
연구 장소
-
-
Alabama
-
Homewood, Alabama, 미국, 35209
- 모병
- Urology Centers of Alabama
-
연락하다:
- Meredith Sharpton, PA-C
- 전화번호: 205-445-0129
- 이메일: msharpton@urologyal.com
-
-
Texas
-
San Antonio, Texas, 미국, 78229
- 모병
- Urology San Antonio
-
연락하다:
- Manuel Hernandez
- 전화번호: 210-617-4116
- 이메일: Manuel.hernandez@usa-clinicaltrials.com
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Signed informed consent form.
- Understands the obligation and is capable of attending all follow-up visits.
- Documented, previously untreated, localized adenocarcinoma of the prostate confirmed by multiparametric MRI and prostate biopsy within 3 months before the first dose.
- Scheduled for radical prostatectomy approximately 12 weeks after the first dose of MVB-101.
- Gleason Grade Group 1 with at least one high-risk feature, or Grade Group 2, 3, or 4. High-risk features for Grade Group 1 are PSA density >0.2 ng/mL/cc, PI-RADS 4 or 5, lesion >1.0 cm, lesion volume >0.4 cc, or risk of extraprostatic extension evidenced by capsular abutment or bulge.
- Prostate-specific antigen 20 ng/mL or less.
- Eastern Cooperative Oncology Group performance status 0 or 1.
- Adequate bone marrow and organ function.
- Sexually active participants agree to use barrier protection during treatment and for 1 month after the last MVB-101 dose.
Exclusion Criteria:
- Any prior treatment for prostate cancer, except prior active surveillance is permitted.
- More than 10 mg/day of systemic steroids within 28 days before signing informed consent.
- Prior exposure to auristatin, an auristatin derivative, or a similar molecule.
- Prior or concurrent malignancy whose natural history or treatment could interfere with or affect MVB-101 safety or efficacy assessments.
- Prostatic calcifications.
- Inability to undergo MRI scanning for any reason, including claustrophobia or implanted devices.
- Major surgery within 4 weeks before first dose or planned during the study, other than prostatectomy.
- Toxicity attributed to prior anticancer therapy, other than alopecia and fatigue, not resolved to Grade 1 or baseline before first dose.
- Poorly controlled concurrent disease, including diabetes or hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg).
- Within 12 months before enrollment: cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery bypass graft surgery, symptomatic peripheral vascular disease, or NYHA class III or IV congestive heart failure.
- History of clinically significant lung disease, including interstitial pneumonia, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis, or suspected disease on screening imaging.
- Active bleeding disorder or other history of Grade 3 or higher hemorrhage within 4 weeks before first dose.
- Need for oral vitamin K antagonist anticoagulant therapy. Low-dose anticoagulants to maintain central venous access patency or prevent deep venous thrombosis and therapeutic low-molecular-weight heparin are permitted.
- Deep vein thrombosis or pulmonary embolism within 6 months before first dose.
- Active infection requiring intravenous antibiotics within 1 week before first dose.
- Uncontrolled HIV, known AIDS, chronic hepatitis B, occult hepatitis B, or hepatitis C.
- Current or anticipated need for a strong CYP3A4 inhibitor or inducer. Prior use requires a washout of 21 days or 5 half-lives, whichever is longer, before first dose.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Part A: MVB-101 1 mg
MVB-101 1 mg by intraprostatic injection once weekly for 4 weeks. |
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E. |
|
실험적: Part A: MVB-101 2 mg
MVB-101 2 mg by intraprostatic injection once weekly for 4 weeks. |
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E. |
|
실험적: Part A: MVB-101 4 mg
MVB-101 4 mg by intraprostatic injection once weekly for 4 weeks. |
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E. |
|
실험적: Part A: MVB-101 8 mg
MVB-101 8 mg by intraprostatic injection once weekly for 4 weeks. |
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E. |
|
실험적: Part B: MVB-101 Dose Expansion
MVB-101 at one or more selected dose levels by intraprostatic injection once weekly for 4 weeks. Other schedules may also be explored. |
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Treatment-emergent adverse events
기간: From first dose through safety follow-up (approximately Day 50); treatment-related adverse events are followed through end of study (approximately Day 90)
|
Number and percentage of participants with treatment-emergent adverse events, treatment-related adverse events, serious adverse events, and clinically significant changes in vital signs, physical examinations, electrocardiogram (ECG) and clinical laboratory tests, graded using NCI CTCAE version 6.0. |
From first dose through safety follow-up (approximately Day 50); treatment-related adverse events are followed through end of study (approximately Day 90)
|
|
Dose-limiting toxicities
기간: Day 1 through Day 29
|
Number and percentage of participants with a dose-limiting toxicity, assessed according to protocol-defined criteria using NCI CTCAE version 6.0. |
Day 1 through Day 29
|
|
Maximum tolerated dose
기간: Through completion of Part A dose escalation, up to 12 months
|
Maximum tolerated dose of intraprostatic MVB-101 determined from dose-limiting toxicities and cumulative safety data under the i3+3 design. |
Through completion of Part A dose escalation, up to 12 months
|
|
Recommended Phase 2 dose
기간: Through completion of dose escalation and applicable dose-expansion, up to 18 months
|
Recommended Phase 2 dose of intraprostatic MVB-101 based on safety, tolerability, pharmacokinetics, and available efficacy data. |
Through completion of dose escalation and applicable dose-expansion, up to 18 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pharmacokinetic parameters of MVB-101 and MMAE
기간: Dose 1 and Dose 3: predose and 0.5, 2, 6, 24, 72, and 168 hours post-dose
|
Plasma concentration-time analysis will be performed using PK concentration values over time. |
Dose 1 and Dose 3: predose and 0.5, 2, 6, 24, 72, and 168 hours post-dose
|
|
Pathological response in excised prostate tissue
기간: At prostatectomy or post-treatment biopsy, approximately Day 90
|
Number and percentage of participants with persistence or absence of the dominant index prostate cancer lesion or any lesion on pathological examination of prostatectomy tissue; post-treatment multicore biopsy is used if planned prostatectomy is not performed. |
At prostatectomy or post-treatment biopsy, approximately Day 90
|
|
Radiologic response by multiparametric MRI
기간: Baseline and approximately 10 days, but no more than 14 days, before prostatectomy
|
Number and percentage of participants with persistence or absence of baseline prostate cancer lesions on post-treatment multiparametric MRI. |
Baseline and approximately 10 days, but no more than 14 days, before prostatectomy
|
|
International Prostate Symptom Score
기간: Baseline through safety follow-up (approximately Day 50)
|
Observed values and change from baseline in International Prostate Symptom Score (IPSS). IPSS score values between 0-5 with lower scores indicating better performance/ improvement. |
Baseline through safety follow-up (approximately Day 50)
|
|
International Index of Erectile Function-5
기간: Baseline through safety follow-up (approximately Day 50)
|
Observed values and change from baseline in International Index of Erectile Function-5 (IIEF-5). IIEF-5 is scored with values 1-5 with higher scores indicating better performance/ improvement. |
Baseline through safety follow-up (approximately Day 50)
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Stephen Snowdy, PhD, MultiValent Biotherapies, Inc.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- MVB-101-101
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .